RadiolabeledNanoparticleQualityChecker

Radiolabeled Nanoparticle Quality Checker — Universal QC for radiolabeled nanocarriers

ℹ️ Utility checks quality of radiolabeled nanoparticles (liposomes, LNPs, polymer NPs) for research use:
• Radionuclide quality: specific activity, radiochemical purity, free radionuclide, parent impurity
• Nanoparticle characteristics: particle size, polydispersity index (PDI), zeta potential
• Safety parameters: pH, endotoxins, sterility, heavy metals
• Adaptive limits based on radionuclide type and target organ

⚠️ IMPORTANT: INVESTIGATIONAL USE ONLY
Radiolabeled nanoparticles are NOT approved by FDA/EMA for clinical use.
All human/animal studies require ethics committee approval.
Parameters are RESEARCH-GRADE estimates and must be validated per study protocol.

Usage:
RadiolabeledNanoparticleQualityChecker.exe → demo mode (console output)
RadiolabeledNanoparticleQualityChecker.exe input.csv output.json → evaluate your data

Input format (CSV):
BatchNumber,Radionuclide,NanoparticleType,TargetOrgan,SpecificActivityMBqPerUmol,RadiochemicalPurityPercent,FreeRadionuclidePercent,ParentNuclideImpurityPercent,ParticleSizeNm,PolydispersityIndex,ZetaPotentialMv,pH,EndotoxinsEU,SterilityTest,HeavyMetalsPPM

Example (sterility: 0=sterile, 1=contaminated; parent impurity: leave blank if N/A):
RN-2026-001,Ga-68,LNP,Lungs,45000.0,94.5,7.0,0.0005,100.0,0.15,-25.0,6.8,120.0,0,5.0

Supported configurations:
• Radionuclides: Ga-68, Zr-89, Cu-64, F-18, I-124
• Nanoparticle types: Liposomes, LNPs, Polymer NPs
• Target organs: Lungs, Liver, Tumor, Spleen

— WHY IS THIS NEEDED?
Radiolabeled nanoparticles represent an emerging class of theranostic agents combining:
• Targeted drug delivery (nanocarrier advantages)
• Real-time biodistribution tracking (radionuclide imaging)
• Potential for image-guided therapy

However, quality control is complex due to dual nature:
• Radiochemical parameters (like traditional radiopharmaceuticals)
• Nanoparticle parameters (size, stability, surface charge)
• Interaction between radionuclide and carrier (affects biodistribution)

⚠️ CRITICAL PARAMETERS:
• Specific activity: Must be sufficient for imaging sensitivity while maintaining nanoparticle integrity
• Radiochemical purity: ≥90% (Ga-68) or ≥95% (Zr-89, Cu-64, F-18, I-124)
• Free radionuclide: ≤10% (Ga-68, I-124) or ≤5% (Zr-89, Cu-64, F-18) — affects biodistribution
• Parent nuclide impurity: ≤0.001% for generator-produced nuclides (Ge-68 for Ga-68)
• Particle size: Organ-specific optimal ranges (e.g., 50-150 nm for lung targeting via capillary entrapment)
• Polydispersity index: ≤0.3 for monodisperse distribution (consistent biodistribution)
• Zeta potential: -30 to +30 mV for colloidal stability

Key features:
• Adaptive parameter limits based on radionuclide and target organ
• Support for 5 radionuclides with different half-lives and applications
• Organ-specific nanoparticle size optimization (lungs vs liver vs tumor)
• Comprehensive safety checks (endotoxins, sterility, heavy metals)
• Research-focused design with clear investigational status disclaimers

Critical parameters by radionuclide:
• Ga-68: Specific activity ≥30 GBq/μmol, purity ≥90%, Ge-68 ≤0.001%, free Ga-68 ≤10%
• Zr-89: Specific activity ≥15 GBq/μmol, purity ≥95%, free Zr-89 ≤5% (78.4h half-life)
• Cu-64: Specific activity ≥20 GBq/μmol, purity ≥95%, free Cu-64 ≤5% (theranostic applications)
• F-18: Specific activity ≥50 GBq/μmol, purity ≥95%, free F-18 ≤5% (short half-life critical)
• I-124: Specific activity ≥10 GBq/μmol, purity ≥90%, free I-124 ≤10% (4.2d half-life)

Nanoparticle size optimization by target:
• Lungs (LNP): 50-150 nm — optimal for capillary entrapment (Nature Biomed Eng 2023)
• Liver (Liposomes): 80-200 nm — Kupffer cell uptake
• Tumor (Liposomes): 100-200 nm — enhanced permeability and retention (EPR) effect
• Spleen (Polymer): 200-500 nm — splenic filtration

💡 Usage tips:
1. Verify radionuclide-specific parameters match your conjugation chemistry
2. Particle size must be measured by DLS (dynamic light scattering) immediately before use
3. Zeta potential indicates colloidal stability — values outside -30 to +30 mV risk aggregation
4. Free radionuclide measurement requires separation method (size exclusion chromatography, dialysis)
5. Document all parameters for ethics committee reporting and study reproducibility

⚠️ Limitations:
• Parameters based on preclinical research — may require adjustment for specific formulations
• Not a substitute for in vivo biodistribution studies
• Utility does NOT replace official pharmacopoeial methods
• Intended for research use only — not for clinical administration
• Final specifications must be validated per local regulatory requirements

Data sources:
• Nature Biomedical Engineering 2023 — Lung-targeted lipid nanoparticles (LuT lipids)
• ACS Nano 2021 — Nanoparticle biodistribution and targeting principles
• Journal of Nuclear Medicine 2022 — Radiolabeled nanoparticle quality control
• European Pharmacopoeia — Radiopharmaceutical specifications
• International Journal of Pharmaceutics 2020 — Liposomal drug delivery systems